Call Boomerang Books 1300 36 33 32

Get Latest Book News + FREE Shipping. Subscribe to the Boomerang Books Bulletin eNewsletter right now!

Description - Drug Efficacy, Safety, and Biologics Discovery by Sean Ekins

Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools covers key emerging technologies in pharmaceutical R & D and how they have substantially impacted (or are currently impacting) drug discovery. The cross-disciplinary collaborations implicit in integrating these technologies with drug discovery operations will fuel the engine for future innovations. This book cuts across the multiple areas of drug discovery, each chapter authored by pioneers in that field, making for a broad appeal to the chemical and biological scientists and technologists involved in drug discovery and development.

Buy Drug Efficacy, Safety, and Biologics Discovery by Sean Ekins from Australia's Online Independent Bookstore, Boomerang Books.

Book Details

ISBN: 9780470225554
ISBN-10: 0470225556
Format: Hardback
(244mm x 165mm x 25mm)
Pages: 408
Imprint: Wiley-Blackwell
Publisher: John Wiley and Sons Ltd
Publish Date: 27-Jan-2009
Country of Publication: United States

Book Reviews - Drug Efficacy, Safety, and Biologics Discovery by Sean Ekins

» Have you read this book? We'd like to know what you think about it - write a review about Drug Efficacy, Safety, and Biologics Discovery book by Sean Ekins and you'll earn 50c in Boomerang Bucks loyalty dollars (you must be a Boomerang Books Account Holder - it's free to sign up and there are great benefits!)

Write Review


Author Biography - Sean Ekins

Sean Ekins, MSc, PHD, DSc, is the Principal at Collaborations in Chemistry; and Adjunct Associate Professor in the Department of Pharmaceutical Sciences at the University of Maryland, School of Pharmacy. Dr. Ekins has published widely on ADME/Tox, systems biology, computational, and in vitro drug discovery approaches. He has previously edited two Wiley books: Computer Applications in Pharmaceutical Research and Development (2006) and Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals (2007). Jinghai J. Xu, PHD, is Director of Automated Biotechnology at Merck. Previously he headed predictive toxicology at Pfizer, where he led research activities in drug-induced liver injury, genetic toxicology, drug transporters, assay development, high content screening, in vitro in vivo correlations, systems biology, and systems toxicology. Dr. Xu has served on steering committees of academic-industry and industry-industry collaborations, and as a guest lecturer at the Massachusetts Institute of Technology.